| First round % (n) | Second round % (n) | Third round % (n) | |
| Cancer | |||
| Total | 12.0 (3464) | 7.0 (3123) | 7.5 (2044) |
| Males | 13.0 (2144) | 7.1 (1911) | 7.7 (1226) |
| Females | 10.2 (1320) | 7.0 (1212) | 7.1 (818) |
| Non-responders in all previous rounds | – | 9.4 (350) | 12.6 (175) |
| Responders in any previous round | – | 6.6 (2125) | 7.1 (1218) |
| Adenoma | |||
| Total | 36.5 (3464) | 30.3 (3123) | 29.1 (2044) |
| Males | 41.6 (2144) | 35.0 (1911) | 33.9 (1226) |
| Females | 28.2 (1320) | 22.8 (1212) | 22.0 (818) |
| Non-responders in all previous rounds | – | 38.0 (350) | 34.9 (175) |
| Responders in any previous round | – | 28.9 (2125) | 28.7 (1218) |
| High-risk adenoma | |||
| Total | 4.3 (3464) | 3.1 (3123) | 3.1 (2044) |
| Males | 5.9 (2144) | 4.3 (1911) | 4.1 (1226) |
| Non-responders in all previous rounds | – | 4.6 (350) | 5.1 (175) |
| Responders in any previous round | – | 2.7 (2125) | 3.0 (1218) |
| Total neoplasia | |||
| Total | 48.4 (3464) | 37.4 (3123) | 36.6 (2044) |
| Males | 54.6 (2144) | 42.1 (1911) | 41.6 (1226) |
| Females | 38.4 (1320) | 29.8 (1212) | 29.1 (818) |
| Cancer+high-risk adenoma | |||
| Total | 16.4 (3464) | 10.1 (3123) | 10.6 (2044) |
| Males | 18.9 (2144) | 11.4 (1911) | 11.8 (1226) |
| Females | 12.0 (1320) | 8.3 (1212) | 8.8 (818) |
| Non-responders in all previous rounds | – | 47.4 (350) | 47.4 (175) |
| Responders in any previous round | – | 35.5 (2125) | 35.8 (1218) |
There was a statistically significant decline in the PPV for cancer between the first and second round (p<0.01, χ2 test), but not between the second and third rounds.
The difference between males and females in all rounds and in all variables was statistically significant at the p<0.01 level, with the exceptions of a positive predictive value for cancer in the second and third rounds (χ2 test).
gFOBT, guaiac faecal occult blood testing.